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778Objectives: Lymph nodemetastasis is among the most important prognostic factors for patients with esophageal
squamous cell carcinoma after curative esophagectomy; however, the extent of lymphadenectomy is still con-
troversial. The objective of the present study was to determine the frequency of lymphatic metastases and to
study the pattern of lymph node metastasis in a large study population.
Methods: The data from 1361 patients with thoracic esophageal squamous cell carcinoma who underwent cu-
rative R0 esophagectomy were retrospectively examined. Logistic regression analysis was used to identify the
factors associated with lymph node metastasis.
Results:Of the 1361 patients, 714 (52.5%) were found to have lymph node metastasis. The frequency of lymph
node metastasis increased as the tumor invasion increased. Paratracheal nodes were the most frequent metastasis
nodes (15.9%). The frequency of lymph node metastasis was 9.8% in the neck, 18.0% in the upper mediasti-
num, 18.9% in the middle mediastinum, 11.8% in the lower mediastinum, and 28.4% in the abdomen. Of these
714 patients, 424 (31.2%) presented with 1 field involvement, 255 (18.7%) with 2 fields, and 35 (2.6%) with 3
fields involvement. Logistic regression analysis revealed tumor length (P<.001), tumor invasion (P<.001),
tumor differentiation (P ¼ .003), and lymphovascular invasion (P<.001) were risk factors for lymph node me-
tastasis. Tumor location (P<.001), tumor invasion (P ¼ .003), lymphovascular invasion (P ¼ .004), and para-
tracheal lymph node involvement (P ¼ .002) were identified as risk factors for cervical lymph node metastasis.
Conclusions:Metastases were more frequent in the abdomen than in the neck. Total mediastinal and upper ab-
dominal lymphadenectomy should be carefully conducted. Certain factors, such as tumor location, depth of tu-
mor invasion, lymphovascular invasion, and paratracheal lymph node involvement, might be helpful in
determining the need to perform cervical lymphadenectomy in individual patients. (J Thorac Cardiovasc
Surg 2012;144:778-86)Earn CME credits at
http://cme.ctsnetjournals.org
Lymph node metastasis (LNM) is one of the most important
factors in predicting the prognosis of patients with esopha-
geal carcinoma,1 but the optimal extent of lymphadenectomy
is still debated.2,3 Studying the pattern ofLNMmight provide
indications of when to perform lymph node dissection in
individual patients. However, published studies of the
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The Journal of Thoracic and Cardiovascular Surgdifferent treatment strategies used.4,5 Therefore, we
reviewed our experience, including all the patients who had
undergone radical lymphadenectomy at Fudan University
Shanghai Cancer Center from 2006 to 2010. The goal of
the present study was to accurately clarify the distribution
of LNMs in thoracic esophageal squamous cell carcinoma
(ESCC), and identify the factors related to LNM.PATIENTS AND METHODS
Patients
The institutional review board of Fudan University Shanghai Cancer
Center approved the database of esophageal carcinoma used for the pres-
ent study. From January 2006 to December 2010, 1562 patients under-
went esophagectomy at Fudan University Shanghai Cancer Center. The
records of all patients with ESCC were reviewed for the present study.
Of these patients, those who underwent transhiatal esophagectomy and
received chemotherapy or radiotherapy before surgery were excluded.
In addition, patients with fewer than 6 lymph nodes removed were ex-
cluded to minimize the potential for understaging. Thus, 1361 patients
with ESCC who had undergone curative R0 transthoracic esophagectomy
were included in the present retrospective study (Figure 1). Of the 1361
patients, 1107 were men (81.3%) and 254 were women (18.7%), with
a mean age of 59  8 years. A total of 294 patients (21.6%) underwent
3-field lymphadenectomy (3-FL) and 1067 (78.4%) 2-FL (Table 1). All
patients were staged according to the TNM classification of the 7th edi-
tion of the American Joint Committee for Caner staging manuals.6 Theery c October 2012
TABLE 1. Patient characteristics (n ¼ 1361)
Characteristic Patients (n)
Age (y)
60 749 (55.0)
>60 612 (45.0)
Gender
Male 1107 (81.3)
Female 254 (18.7)
Tumor length (cm)
25th percentile 2.5
50th percentile 3.5
75th percentile 4.5
T classification
Tis 12 (0.9)
T1 185 (13.6)
T2 353 (25.9)
T3 772 (56.7)
T4a 39 (2.9)
N classification
N0 647 (47.5)
N1 396 (29.1)
N2 217 (15.9)
N3 101 (7.4)
Lymphovascular invasion
Yes 266 (19.5)
No 1095 (80.5)
Tumor differentiation
Well 132 (9.7)
Moderate 903 (66.3)
Poor 326 (24)
Abbreviations and Acronyms
2-FL ¼ 2-field lymphadenectomy
3-FL ¼ 3-field lymphadenectomy
CT ¼ computed tomography
ESCC ¼ esophageal squamous cell carcinoma
LNM ¼ lymph node metastasis
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IB in 115 (8.4%), stage IIA in 186 (13.7%), stage IIB in 437 (32.1%),
stage IIIA in 312 (22.9%), stage IIIB in 153 (11.2%), and stage IIIC in
123 (9.0%) patients.
Preoperative Workup
According to the practice guidelines of the Shanghai Cancer Center, the
preoperative workup included a complete history, physical examination,
endoscopy of the upper gastrointestinal tract, computed tomography
(CT) of the chest, and ultrasonography/CT of the neck and abdomen. His-
tologic confirmation of the carcinoma by endoscopy was also required.
Positron emission tomography/CT and endoscopic ultrasonography were
not routinely performed. On the basis of the results from these examina-
tions, the patients who were medically suitable, with stage T1-T3 tumors
without distant metastases would undergo surgery.
Surgical Procedure
In our hospital, 3 procedures were mainly conducted. The 3-incision
McKeown procedure was usually performed for tumors in the upper loca-
tion, and the 2-incision Ivor-Lewis procedure and single-incision Sweet ap-
proach were always performed for tumors in the middle and lower
locations. However, the choice of approach also depended on surgeonPatients who underwent esophagectomy 
from 2006 to 2010 (n=1562)
Squamous cell carcinomas were included 
(n=1491)
Patients included for this study (n=1361)
Exclusion criteria:
Transhiatal esophagectomy (n=18)
Chemotherapy and/or radiotherapy prior to 
surgery (n=30)
Less than 6 lymph nodes (n=82)
Upper esophagus 
(n=87)
Middle esophagus 
(n=818)
Lower esophagus 
(n=456)
Mckeown procedure (n=83)
Ivor-Lewis procedure (n=4)
Mckeown procedure (n=384)
Ivor-Lewis procedure (n=398)
Sweet procedure (n=36)
Mckeown procedure (n=102)
Ivor-Lewis procedure (n=276)
Sweet procedure (n=78)
FIGURE 1. Patient disposition chart.
Data in parentheses are percentages.
The Journal of Thoracic and Capreference. In the right thoracic procedures (McKeown and Ivor-Lewis pro-
cedures), a muscle-sparing incision was made in the fourth intercostal
space, the azygos vein was ligated and dissected, the esophagus was mobi-
lized and dissected from the apex of the chest to diaphragmatic level, and
thoracic duct was routinely ligated above the diaphragm. During mobiliza-
tion of the stomach, the left gastric vein and artery were isolated and closed,
and the right gastroepiploic vessels were carefully preserved. A gastric
tube, about 4 cm in width, was completed along the greater curvature. In
theMcKeown procedure, the gastric tubewas drawn to the left neck through
the retrosternal route or posterior mediastinal route, and an end-to-end
esophagogastric anastomosis was completed with manual suturing. In the
Ivor-Lewis procedure, the gastric tube was pulled into the chest, and an
end-to-side circular stapled anastomosis was made. In the left thoracic pro-
cedure (Sweet procedure), an incision through the sixth or seventh intercos-
tal space was performed, the diaphragm was incised to gain sufficient
exposure for the operation, and an end-to-side esophagogastric anastomosis
was completed in the left chest with a circular stapler. In the present study,
the gastric conduit was used as reconstruction substitute in all the patients.
Lymphadenectomy
Total mediastinal lymphadenectomy was routinely performed through
a right thoracotomy (McKeown and Ivor-Lewis procedures), and through
a left thoracotomy, usually the middle and lower mediastinal nodes and
upper abdominal nodes were removed. When lymphatic involvement
in the neck was indicated by CT scan or ultrasonography, cervical lympha-
denectomy was performed through a collar incision (Table 2). The resected
lymph nodes were labeled for pathologic examination according to the an-
atomic sites. In the present study, the cervical lymph nodes included therdiovascular Surgery c Volume 144, Number 4 779
TABLE 2. Extent of lymphadenectomy and number of lymph nodes sampled
Variable 3-FL (n ¼ 294)
2-FL
Right thoracotomy (n ¼953) Left thoracotomy (n ¼ 114)
Neck 294 (100.0), 9/14/21
Upper mediastinum 212 (72.1), 0/2/5 698 (73.2), 0/2/5 40 (35.1), 0/0/1
Middle mediastinum 266 (90.5), 2/5/9 855 (89.7), 3/6/10 86 (75.4), 1/4/9
Lower mediastinum 154 (52.4), 0/1/2 572 (60.0), 0/1/3 99 (86.8), 2/4/6
Abdomen 267 (90.8), 4/8/11 901 (94.5), 5/8/13 98 (86.0), 3/7/12
Total 294 (100), 25/32/43 953 (100), 14/20/27 114 (100), 12/18/26
Data presented as number of patients with lymph nodes sampled, with percentages in parentheses, followed by 25th/50th/75th percentiles. 2-FL, 2-Field lymphadenectomy; 3-FL,
3-field lymphadenectomy.
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The upper mediastinal nodes included the upper paraesophageal lymph no-
des and bilateral paratracheal lymph nodes. The middle mediastinal nodes
included the subcarinal, middle paraesophageal, and bilateral hilar lymph
nodes. The lower mediastinal nodes included the lower paraesophageal,
posterior mediastinal, and diaphragmatic lymph nodes. The upper abdom-
inal nodes included the paracardial, lesser curvature, greater curvature, left
gastric, common hepatic, splenic, and celiac lymph nodes.
Statistical Analysis
Statistical analysis was performed using the SPSS statistical software,
version 16.0 (SPSS, Chicago, Ill). Categorical variables were summarized
as the frequencies and percentages. For the variables significantly associ-
ated with lymphatic involvement, we then fit a multivariate logistic regres-
sion model (forward stepwise procedure) to identify the risk factors
significant for LMNs. The results were considered significant for P<.05.
RESULTS
A total of 33,253 lymph nodes were removed (median,
23; 25th and 75th percentiles, 15 and 31). Of the 1361 pa-
tients, 714 (52.5%) had 2634 positive lymph nodes.
Pattern of LNMs
No patient with stage Tis tumor was found to have LNM.
As the depth of tumor invasion increased, both the fre-
quency of LNMs and the number of positive lymph nodes
increased (Figure 2). For stage T1 tumors, LNMs occurredFIGURE 2. The frequency of lymph node metast
780 The Journal of Thoracic and Cardiovascular Surgin 1 (2.2%) of 45 patients with tumor limited to the mucosa
(stage T1a), but in 46 (32.9%) of 140 patients with tumor
infiltrating the submucosa (stageT1b).
Of all the LNMs, the paratracheal lymph nodes were the
most frequently involved (15.9%), followed by the middle
paraesophageal (14%) and paracardial (11.2%) lymph no-
des. A good relationship was seen between the tumor loca-
tion and LNM regions. Cervical involvement was more
frequent in patients with tumor in the upper location, and
abdominal involvement was more frequent in patients
with tumor in the lower location. LNMs in the upper medi-
astinum were common, regardless of the tumor location
(Figure 3 and Table 3).
More LNMs developed in patients who had undergone
3-FL (69%). The reason might have been related to our se-
lection bias. ‘‘Skipping metastasis,’’ referring to a patient
with cervical and/or abdominal involvement but no medias-
tinal metastasis, developed in 197 (27.6%) of 714 patients
with positive lymph nodes (63 patients had undergone
3-FL and 134, 2-FL; Table 4).
Risk Factors for LNMs
Male gender, deeper tumor invasion, greater tumor
length, poor tumor differentiation, and lymphovascular in-
vasion were associated with a greater occurrence of LNMs.ases according to the depth of tumor invasion.
ery c October 2012
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FIGURE 3. The frequency of lymph node metastasis according to the anatomic site.
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cation and paratracheal LNM (Table 5). Multivariate logis-
tic regression analysis identified that greater tumor length
(P<.001), deeper tumor invasion (P<.001), poor tumor
differentiation (P ¼ .003), and lymphovascular invasion
(P < .001) correlated with the occurrence of LNMs
(Table 6). In contrast, an upper tumor location
(P < .001), deeper tumor invasion (P ¼ .003),The Journal of Thoracic and Calymphovascular invasion (P ¼ .004), and paratracheal
LNM (P ¼ .002) were identified as risk factors for cervical
involvement (Table 7).
DISCUSSION
Lymph node status, such as the number of positive nodes,
number of fields with LNMs, and lymph node ratio, are
among the most important predictors for survival afterrdiovascular Surgery c Volume 144, Number 4 781
TABLE 3. Regions of lymph node metastases according to tumor location
Variable
Tumor location
Total (n ¼ 1361)Upper (n ¼ 87) Middle (n ¼ 818) Lower (n ¼ 456)
Neck 21 (24.1) 87 (10.6) 25 (5.5) 133 (9.8)
Upper mediastinum 36 (41.4) 156 (19.1) 53 (11.6) 245 (18.0)
Middle mediastinum 9 (10.3) 197 (24.1) 51 (11.2) 257 (18.9)
Lower mediastinum 3 (3.4) 62 (7.6) 96 (21.1) 161 (11.8)
Abdomen 9 (10.3) 196 (24.8) 181 (39.7) 386 (28.4)
Data presented as number of patients, with percentages in parentheses.
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Sesophagectomy.7,8 However, it is still under debate about
the extent of lymphadenectomy needed because of several
factors, such as early lymphatic spread, complex distant
metastasis, and unsatisfied prognosis after surgery. The
present study determined the pattern of lymphatic spread
by reviewing the data from all 1361 patients with ESCC
who had undergone radical lymphadenectomy during the
past 5 years at our hospital and the factors associated with
LNMs. From these results, we hoped to provide useful
information for guiding lymphadenectomy and future
clinical trials.
LNM was found in 714 (52.5%) of the 1361 patients and
mostly occurred in the paratracheal, paraesophageal, and
paracardial lymph nodes. Moreover, regarding the abdomi-
nal LNMs, we found the LNM mostly occurred in the peri-
gastric areas, but common hepatic, splenic, and celiac
LNMs were rare. These results confirmed the anatomic
observations9-11 that a long longitudinal extension of
lymphatic drainage in the submucosa is connected to the
superior mediastinum along the recurrent nerve and
paracardial lymphatics. The lymph nodes in these sites
should be carefully resected for tumor staging and to
reduce local recurrence. In addition, good correlation was
found between adjacent regional lymph node involvement
and the tumor location. LNM was more frequent in the
cervical area with tumors in the upper esophagus, but
for middle and lower tumors, LNM was more frequent
in the abdomen. We also found that LNMs in theTABLE 4. Number of regions with lymph node metastasis
Region (n) Positive lymph node region 3-FL (n
None 91 (
1
Neck 38 (
Mediastinum 42 (
Abdomen 12 (
2
Mediastinum and neck 47 (
Abdomen and neck 13 (
Mediastinum and abdomen 16 (
3
Neck, mediastinum, abdomen 35 (
Data presented as number of patients, with percentages in parentheses. 3-FL, 3-Field lym
782 The Journal of Thoracic and Cardiovascular Surgupper mediastinum were common, regardless of the tumor
location. On the basis of our data, we believe right
thoracotomy with careful lymph node resection in the
upper mediastinum should be conducted for curative intent.
Sentinel lymph node biopsy has become the reference
standard for some superficial cancers; however, its use in
ESCC is limited and controversial.12,13 Tumor cells can
spread along the submucosal lymphatic channel for a long
distance before entering the paraesophageal lymph nodes.
Therefore, the presence of skip metastases was common in
our patients with ESCC. A total of 197 patients (27.6%)
presented with skip metastases in the cranial and/or caudal
directions without mediastinal LNMs. Cranial skip
metastases occurred more frequently in patients who had
undergone 3-FL, and caudal skip metastases were much
more common overall. Thus, it would seem difficult to de-
fine the proper sentinel lymph node for ESCC.
The depth of tumor invasion was associated with LNMs
and the number of positive lymph nodes. Once the tumor
cells have breached the basement membrane of the epithe-
lium, potential metastasis can develop.14 The cells spread
from the mucosal lymphatic ducts to drain into a rich sub-
mucosal plexus and can then spread longitudinally through
this dense lymphatic network and invade the paraesopha-
geal lymphatic system. In addition to the deeper tumor in-
vasion, a greater tumor length, poor tumor differentiation,
and lymphovascular invasion were also identified as risk
factors associated with LNM in our study. Our results¼ 294) 2-FL (n ¼ 1067) Total (n ¼ 1361)
31.0) 556 (52.1) 647 (47.5)
12.9) — 38 (2.8)
14.3) 198 (18.6) 240 (17.6)
4.1) 134 (12.6) 146 (10.7)
16.0) — 47 (3.5)
4.4) — 13 (1.0)
5.4) 179 (16.8) 195 (14.3)
11.9) — 35 (2.6)
phadenectomy; 2-FL, 2-field lymphadenectomy.
ery c October 2012
TABLE 5. Prevalence of lymph node metastases and cervical involvement according to patient and tumor characteristics
Characteristic Patients (n)
LNMs Cervical involvement
n (%) P value n (%) P value
Gender <.001 .509
Male 1107 608 (54.9) 111 (10.0)
Female 254 106 (41.7) 22 (8.7)
Age (y) .154 .740
60 749 406 (54.2) 75 (10.0)
>60 612 308 (50.3) 58 (9.5)
Tumor location .284 <.001
Upper 87 49 (56.3) 21 (24.1)
Middle 818 415 (50.7) 87 (10.6)
Lower 456 250 (54.8) 25 (5.5)
Tumor length (cm) <.001 .007
0-0.9 46 13 (28.3) 1 (2.2)
1-1.9 230 85 (37.0) 15 (6.5)
2-2.9 357 175 (49.0) 28 (7.8)
3 728 441 (60.6) 89 (12.2)
T classification <.001 <.001
Tis-T1 197 47 (23.9) 4 (2.0)
T2 353 167 (47.3) 29 (8.2)
T3 772 471 (61.0) 92 (11.9)
T4a 39 29 (74.4) 8 (20.5)
Tumor differentiation <.001 .386
Well 132 42 (31.8) 9 (6.8)
Moderate 903 476 (52.7) 88 (9.7)
Poor 326 196 (60.1) 36 (11.0)
Lymphovascular invasion <.001 <.001
Yes 266 232 (87.2) 45 (16.9)
No 1095 482 (44.0) 88 (8.0)
Paratracheal node involvement <.001
Yes 217 41 (18.9)
No 1144 92 (8.0)
LNM, Lymph node metastasis.
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studies,15,16 and we believe all these factors should be
considered when evaluating the lymph nodes status and
therapeutic decision-making.
The International Society for Diseases of the Esophagus
has classified the extent of lymphadenectomy as standard,
extended, total, and 3-FL.17 However, the optimal extentTABLE 6. Multivariate analysis of factors associatedwith lymph node
metastasis
OR 95% CI P value
Tumor length
(per 1-cm increase)
1.245 1.150-1.348 <.001
Tumor invasion depth
(T3-T4/Tis-T2)
1.719 1.343-2.201 <.001
Tumor differentiation
(poor/well-moderate)
1.509 1.145-1.988 .003
Lymphovascular invasion
(yes/no)
7.817 5.311-11.504 <.001
CI, Confidence interval; OR, odds ratio.
The Journal of Thoracic and Caof lymphadenectomy remains controversial. In China, left
thoracotomy has been widely performed; however, this pro-
cedure does not resect the lymph nodes in the upper medi-
astinum. From our retrospective analysis, and despite the
long-term survival, we propose that extended total medias-
tinal lymphadenectomy through a right thoracotomy should
be conducted. In the present study, in addition to the upper
tumor location, deeper tumor invasion, and lymphovascular
invasion, paratracheal lymph node involvement was identi-
fied as a risk factor for cervical lymph node metastases. This
result is consistent with the findings from previousTABLE 7. Multivariate analysis of factors associated with cervical
lymph node metastasis
OR 95% CI P value
Tumor location (upper/middle-lower) 2.973 1.707-5.176 <.001
Tumor invasion depth (T3-T4/Tis-T2) 1.905 1.248-2.908 .003
Lymphovascular invasion (yes/no) 1.835 1.220-2.761 .004
Paratracheal node involvement (yes/no) 1.984 1.299-3.029 .002
CI, Confidence interval; OR, odds ratio.
rdiovascular Surgery c Volume 144, Number 4 783
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diotherapy to the cervical region should be indicated for pa-
tients with positive paratracheal lymph nodes after 2-FL.
The pattern of lymphatic spread in our study differed
from those of previous reports owing to different treatment
strategies. The frequency of metastases was 9.8%, 18.0%,
18.9%, 11.8%, and 28.4% in the cervical, upper, middle,
lower mediastinal lymph nodes and abdominal lymph nodes
in the present retrospective study, respectively. The corre-
sponding frequencies were 35.6%, 22.2%, 26.5%, 6.1%,
and 26.5% in 1850 patients with ESCC reported by
Chen and colleagues4 and 3.8%, 5.0%, 28.6%, 16.5%,
and 21.6% in 1077 patients reported by Huang and col-
leagues.5 One major reason was the varying extent of lym-
phadenectomy. Because 3-FL was selectively conducted
according to the CT and ultrasound findings in our center,
we considered the patients who underwent 2-FL as under-
going radical surgery without cervical involvement and in-
cluded all these patients in the present analysis to balance
the selection bias. The other reason was the different patient
cohorts. More superficial esophageal cancer (stage Tis-T1)
was present in our research, and the proportion was 14.5%
compared with about 5% in the other 2 studies.
Strengths and Limitations
The present study is one of the largest series to determine
the pattern of LNMs in patients with thoracic ESCC. The
database originated from a single, high-volume institute
within a short period; thus, the data were more homogenous
because the surgeons’ practice patterns were more likely to
be uniform. According to the pattern of lymphatic spread in
the present study, we emphasized the importance of lym-
phadenectomy in the upper mediastinum. However, the
present study had several limitations. First, it was a retro-
spective study, and the exact lymph node status could
have been affected by the surgery types and surgeon prefer-
ences. Second, micrometastases in the lymph nodes of
patients with stage N0 on routine histopathologic examina-
tion are reported to be frequent.19 However, we did not rou-
tinely examine this, although it had an influence on the real
lymphatic status. Moreover, cervical lymphadenectomy
was performed in selected patients according to our practice
guidelines. Although cervical ultrasound examination was
sufficient in the assessment of cervical nodal involvement
with high sensitivity and specificity,20 the incidence of cer-
vical metastases in the present study was underestimated
owing to the image technology’s limitations. The optimal
extent of lymphadenectomy and the treatment strategy re-
main unanswered because of the lack of large prospective
studies; thus, more research is still needed.
CONCLUSIONS
The mediastinum and abdomen are the predominant
areas in which LNMs occurred more frequently in ESCC.784 The Journal of Thoracic and Cardiovascular SurgExtended total mediastinal and upper abdominal lymphade-
nectomy should be carefully performed. The depth of tumor
invasion, lymphovascular invasion, and paratracheal lymph
node involvement, together with the tumor location, might
help us to conduct cervical lymphadenectomy individually
in patients with ESCC.References
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DrAntoon Lerut (Leuven, Belgium). Thank you, Dr Li, for this
excellent presentation on an interesting topic, and thank you also
for providing me with the manuscript well in advance.
In 1994, Dr Akiyama from Tokyo published in the Annals of
Surgery his landmark report on radical lymph node dissection
for cancer of the thoracic esophagus. His publication focused on
a meticulous analysis of the pattern of lymph node spread in a se-
ries of 290 patients who all underwent 3-FL during a period span-
ning 20 years. Your presentation, now 20 years later, has the
advantage that it included a very large cohort of 1361 patients
within a short period of barely 5 years, making, of course,
a much larger and more coherent group.
In the report by Akiyama, the incidence of cervical lymph node
involvement was 38% overall, and for lower esophageal tumors,
was as much as 27%, indicating that, indeed, as you mentioned
in your report, there is in your study material a bias in the sense
that you performed 3-FL in only 21% of your patients. Moreover,
those were the patients who had on CTor ultrasound scan, a suspi-
cion of positive lymph nodes in the neck.
I alsowould like to quote another publication, again from Japan,
by Dr Nishimaki, on 3-FL, but this time specifically for early T1
tumors. In that report, 57% of the patients had positive nodes, of
which as much as 16% were, again, in the cervical region.
Within this context, I have 3 questions. First, the purpose of
your study was to obtain useful information to guide lymphade-
nectomy. Given the probably greater incidence of positive lymph
nodes in the neck than you actually reported, would you consider
performing systematic biopsy and frozen section analysis of the in-
trathoracic high paratracheal lymph node chain, and, in case of
a positive report, would you then perform systematic cervical lym-
phadenectomy, in addition to the thoracic and abdominal compart-
ments, irrespective of the tumor location and negative CT or
ultrasound findings?
Dr Li. Thank you for your question, Professor Lerut.
This was a retrospective study, and we included all the patients
who had undergone radical lymphadenectomy. Obviously, there
was a selection bias in our study. At present, we cannot conduct
cervical lymphadenectomy unselectively because of surgeon pref-
erence and in consideration of the high incidence of postoperative
complications. Thus, the bias was present. However, it could be
true that we could use the intraoperative information to select pa-
tients for cervical lymphadenectomy individually.
Dr Lerut. In the future?
Dr Li. Yes, and we will work on this aspect.
Dr Lerut. Thank you.
My second question—you did not speak on the number of in-
volved lymph nodes. Is there a correlation between the number
of positive intrathoracic lymph nodes and, again, the probability
of having lymph node involvement in the cervical region? Further-
more, you showed that in T1 tumors you had an approximately
20% incidence of overall positive lymph node involvement. DidThe Journal of Thoracic and Cayou have an opportunity to study the subdivision of the T1b tumors
in submucosal area (sm)1, sm2, sm3? That correlates, of course,
with the whole discussion on the indications for endoluminal
therapies.
Dr Li. It is true a relationship exists between the number of pos-
itive lymph nodes in the mediastinum and metastasis in the cervi-
cal region in our analysis. Because of our selection bias for the
patients who underwent 3-FL, more positive lymph nodes were
usually found in the patients with an advanced tumor stage.
Regarding the subclassification of the T1b tumors, actually we
only just finished this work last month. The proportion of superfi-
cial cancer was not large in our center, and it was about 15% in
total. The incidence of metastases for sm1 and sm2 tumors was
about 20%, and it was about 38% for the sm3 tumors.
Dr Lerut. So sm1 and sm2 was 20% overall?
Dr Li.Yes, it was about 20% for sm1 and sm2 overall and about
30% for T1b tumors overall.
Dr Lerut. My third question is a more general question. The
purpose of your study was also to obtain useful information for fu-
ture clinical trials. In the United States and in Europe as well, most
patients with the finding of 1 or more positive nodes on clinical
staging currently will be treated with induction chemotherapy or
chemoradiotherapy. From your report, it appears that only a small
minority of patients received induction therapy. Thus, from your
results and given the well-known negative prognostic effect of
lymph node involvement, which was present in more than one
half of your patients, are you considering to opt for induction ther-
apy for patients who, on clinical staging, have positive nodes or do
you believe that primary surgery with radical lymphadenectomy is
to be preferred?
I would like to thank the Association for the privilege to discuss
this highly interesting presentation.
Dr Li. In fact, induction therapy before surgery, or neoadjuvant
chemotherapy or chemoradiotherapy, was not usually performed
in our institution. Only 30 patients received chemotherapy or ra-
diotherapy before surgery. However, in fact, what they received
could not be regard as induction therapy or neoadjuvant therapy,
because some of these patients underwent surgery owing to recur-
rence after radiotherapy, and some underwent surgery because
they refused the chemotherapy after 1 or 2 cycles; they had
changed their minds and requested surgery. Thus, we excluded
these patients from the present study, and the proportion of these
patients was small.
Dr Lerut. But would you in the future consider an increase in
the indications for induction therapy?
Dr Li. Neoadjuvant therapy might be of benefit, and we will
change our treatment strategy according to the findings of future
clinical trials. But, at present, surgeons and most of the patients
in our institution prefer surgery as the first choice.
Dr Lerut. Clever patients.
Dr Haiquan Chen (Shanghai, China). If I might answer the
question, for squamous cell carcinoma, no data are available to
show that neoadjuvant chemotherapy has a positive result. So, per-
haps we will try that. We have a lot of patients. Perhaps we can ini-
tiate that trial.
Speaking of the sm1, sm2, and sm3, that is a new concept. We
asked the pathologist to go back and review that in all the patho-
logic specimens. Our results on that study will come out soon.rdiovascular Surgery c Volume 144, Number 4 785
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SDr Lerut. We are looking forward to that study next year.
DrChen. Sm1 and sm2, that was about 20%, with no difference
in sm1, sm2. However, sm3 was 38%. That was high.
Dr Nasser K. Altorki (New York, NY). I enjoyed your
presentation.
I just want to clarify something. When you speak about the par-
atracheal lymph nodes, that constitutes multiple stations of lymph
nodes. What specific nodal stations did you actually dissect in the
paratracheal area? Was that 2, 3, or 4?
Dr Chen (Shanghai, China). Yes, there were several. Both bi-
lateral recurrent nerves, specifically that level, bilateral recurrent
nerves.
Dr Altorki. Do you dissect 2 or 4?786 The Journal of Thoracic and Cardiovascular SurgDr Chen. For Ivor-Lewis, we do bilateral; the lymph nodes
along the right recurrent nerve and left recurrent nerve were all
removed.
Dr Altorki. Yes, but you did not dissect anything in front of the
trachea.
Dr Chen. Yes, because metastasis in this region was rare ac-
cording to our data, we did not routinely remove the lymph nodes
anterior to the trachea.
Dr Altorki. I agree. I just wanted to make sure. I think it is im-
portant that when you state paratracheal that you actually specify
the precise nodal station, because it could be commonly understood
to include the nodes behind the cava and in front of the trachea.
Dr Chen. Yes, that is true.ery c October 2012
